Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and Chemoradiation in Resectable Esophageal Cancer
NCT03087864Phase 2Completed
- Sponsor
- University of Amsterdam
- Start
- Jun 2017
- Primary completion
- Jul 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in esophageal adenocarcinoma (EAC), sponsored by University of Amsterdam. Started Jun 2017; status: completed.
02
Drugs
atezolizumab
03
Conditions
esophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT03087864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03087864.